SwePub
Sök i LIBRIS databas

  Extended search

L773:1933 7213
 

Search: L773:1933 7213 > A Brain-Targeting B...

A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice

Rofo, Fadi (author)
Uppsala universitet,Institutionen för farmaci
Meier, Silvio R. (author)
Uppsala universitet,Institutionen för folkhälso- och vårdvetenskap
Metzendorf, Nicole G., 1979- (author)
Uppsala universitet,Institutionen för farmaci,Protein drug design
show more...
Morrison, Jamie (author)
Uppsala universitet,Institutionen för farmaci,Protein drug design
Petrovic, Alex (author)
Uppsala universitet,Institutionen för farmaci,Protein drug design
Syvänen, Stina (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Geriatrik
Sehlin, Dag, 1976- (author)
Uppsala universitet,Institutionen för folkhälso- och vårdvetenskap
Hultqvist, Greta, 1980- (author)
Uppsala universitet,Institutionen för farmaci,Protein drug design
show less...
 (creator_code:org_t)
2022-08-08
2022
English.
In: NEUROTHERAPEUTICS. - : Springer Nature. - 1933-7213 .- 1878-7479. ; 19:5, s. 1588-1602
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Amyloid-beta (A beta) oligomers and protofibrils are suggested to be the most neurotoxic A beta species in Alzheimer's disease (AD). Hence, antibodies with strong and selective binding to these soluble A beta aggregates are of therapeutic potential. We have recently introduced HexaRmAb158, a multivalent antibody with additional A beta-binding sites in the form of single-chain fragment variables (scFv) on the N-terminal ends of A beta protofibril selective antibody (RmAb158). Due to the additional binding sites and the short distance between them, HexaRmAb158 displayed a slow dissociation from protofibrils and strong binding to oligomers in vitro. In the current study, we aimed at investigating the therapeutic potential of this antibody format in vivo using mouse models of AD. To enhance BBB delivery, the transferrin receptor (TfR) binding moiety (scFv8D3) was added, forming the Bispecific-multivalent antibody (HexaRmAb158-scFv8D3). The new antibody displayed a weaker TfR binding compared to the previously developed RmAb158-scFv8D3 and was less efficiently transcytosed in a cell-based BBB model. HexaRmAb158 detected soluble A beta aggregates derived from brains of tg-ArcSwe and App(NL-G-F) mice more efficiently compared to RmAb158. When intravenously injected, HexaRmAb158-scFv8D3 was actively transported over the BBB into the brain in vivo. Brain uptake was marginally lower than that of RmAb158-scFv8D3, but significantly higher than observed for conventional IgG antibodies. Both antibody formats displayed similar brain retention (72 h post injection) and equal capacity in clearing soluble A beta aggregates in tg-ArcSwe mice. In conclusion, we demonstrate a Bispecific-multivalent antibody format capable of passing the BBB and targeting a wide-range of sizes of soluble A beta aggregates.

Subject headings

NATURVETENSKAP  -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)

Keyword

Multivalent antibodies
Bispecific
A beta
Oligomers
BBB
Mouse models

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view